Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.

Keiko ImamuraYuishin IzumiHaruhiko BannoRyuji UozumiSatoshi MoritaNaohiro EgawaTakashi AyakiMakiko NagaiKazutoshi NishiyamaYasuhiro WatanabeRitsuko HanajimaRyosuke OkiKoji FujitaNaoto TakahashiTakafumi IkedaAkira ShimizuAkiko MorinagaTomoko HirohashiYosuke FujiiRyosuke TakahashiHaruhisa Inoue

Published in: BMJ open (2019)

UMIN000036295; Pre-results, JMA-IIA00419; Pre-results.

Keyphrases

amyotrophic lateral sclerosis
stem cells
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
drug induced
randomized controlled trial
high glucose
clinical trial
bone marrow
diabetic rats
cell therapy
patient reported